Incyte Corporation - Common Stock (NQ:INCY)

115.71 -1.22 (-1.04%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)

June 08, 2021

From Incyte

Via Business Wire

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

June 04, 2021

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...

From MorphoSys AG

Via AccessWire

Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

June 04, 2021

From Incyte

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial ↗

June 02, 2021

Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of...

Via Benzinga

Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover ↗

June 02, 2021

MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.

Via Investor's Business Daily

BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients ↗

June 02, 2021

BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗

June 01, 2021

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...

Via Benzinga

Week In Review: Nikang Raises $200 Million From US And China Investors ↗

May 29, 2021

NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. NiKang was originally incubated by CBC Group (C-Bridge Capital) in...

Via Talk Markets

Incyte to Present at Upcoming Investor Conferences

May 20, 2021

From Incyte

Via Business Wire

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

May 19, 2021

From Incyte

Via Business Wire

Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions ↗

May 17, 2021

Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in...

Via Benzinga

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

May 17, 2021

From Incyte

Via Business Wire

The QQQ Was Hammered Again Today. Here's Why. ↗

May 12, 2021

U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks.

Via Benzinga

Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

May 12, 2021

From Incyte

Via Business Wire

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

Incyte Corp (INCY) Q1 2021 Earnings Call Transcript ↗

May 04, 2021

INCY earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance ↗

May 04, 2021

Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of...

Via Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Recap: Incyte Q1 Earnings ↗

May 04, 2021

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which...

Via Benzinga

Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 04, 2021

From Incyte

Via Business Wire

Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021

May 03, 2021

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

April 27, 2021

From Incyte

Via Business Wire

Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies ↗

April 23, 2021

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream...

Via Benzinga

Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

April 23, 2021

From Incyte

Via Business Wire

Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis

April 23, 2021

From Incyte

Via Business Wire

Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience

April 20, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

April 19, 2021

From Incyte and MorphoSys AG

Via Business Wire

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.